B7-33
Single-chain peptide derivative of relaxin. Designed to retain anti-fibrotic activity without the cardiovascular side profile of full relaxin. Pre-clinical / early human research.
B7-33 is a single-chain fragment of relaxin designed to keep the anti-fibrotic effect (good for hearts, kidneys, lungs) without dropping blood pressure (the side effect of full relaxin). Pre-clinical only. Don't use this without medical oversight.
Not FDA approved. Pre-clinical research compound.
Not formally categorized in the FDA bulks lists.
Not prescribed in conventional medicine.
Who it's for
- →Researchers studying fibrotic disease pathways
- →Cardiovascular-research context only
- →Educational reference — not for community use
What to expect
- Week 1
No documented human user reports of acute effects.
- Week 4
Pre-clinical models show anti-fibrotic markers shifting around here.
- Week 8
No long-term human data exists.
How it works (mechanism)
Single-chain peptide derivative of relaxin that retains binding to relaxin receptor RXFP1 with anti-fibrotic signaling, but lacks the cardiovascular receptor crosstalk responsible for relaxin's hypotensive effect.
Dosing protocol
No human protocol exists. Animal-model dosing is per-kg and not directly translatable.
Stacks well with
Side effects
When NOT to use
- ⚠Hypotension or unstable cardiovascular status
- ⚠Pregnancy / nursing
- ⚠Anyone risk-averse to pre-clinical-only data
Common mistakes
- • Treating community-vendor B7-33 as research-grade clinical material
- • Running it without published human safety data
- • Stacking it with anything else
Educational only. User-specific dosing is between you and a qualified provider.
Frequently asked
What is B7-33?+
Is B7-33 FDA approved?+
Is B7-33 banned by WADA?+
Are you still natty after taking B7-33?+
Do doctors prescribe B7-33?+
What's the typical dose of B7-33?+
What are the side effects of B7-33?+
How long until B7-33 starts working?+
More in Healing
Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing.
A fragment of Thymosin Beta-4. Drives cell migration and tissue repair, used for chronic soft-tissue stuff.
Parathyroid-hormone fragment (PTH 1-34). FDA-approved as Forteo for severe osteoporosis. Anabolic for bone — opposite of bisphosphonates.
EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin. Studied for neuropathic pain, sarcoidosis, diabetic complications.